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Modulation of osteogenic and
myogenic differentiation by a
phytoestrogen formononetin via
p38MAPK-dependent JAK-STAT
and Smad-1/5/8 signaling pathways
in mouse myogenic progenitor cells
Ilavenil Soundharrajan1, Da Hye Kim2, Palaniselvam Kuppusamy1 & Ki Choon Choi1
Formononetin (FN), a typical phytoestrogen has attracted substantial attention as a novel agent
because of its diverse biological activities including, osteogenic differentiation. However, the molecular
mechanisms underlying osteogenic and myogenic differentiation by FN in C2C12 progenitor cells
remain unknown. Therefore the objective of the current study was to investigate the action of FN
on myogenic and osteogenic differentiation and its impact on signaling pathways in C2C12 cells. FN
significantly increased myogenic markers such as Myogenin, myosin heavy chains, and myogenic
differentiation 1 (MyoD). In addition, the expression of osteogenic specific genes alkaline phosphatase
(ALP), Run-related transcription factor 2(RUNX2), and osteocalcin (OCN) were up-regulated by FN
treatment. Moreover, FN enhanced the ALP level, calcium deposition and the expression of bone
morphogenetic protein isoform (BMPs). Signal transduction pathways mediated by p38 mitogenactivated protein kinase (p38MAPK), extracellular signal-related kinases (ERKs), protein kinase B (Akt),
Janus kinases (JAKs), and signal transducer activator of transcription proteins (STATs) in myogenic and
osteogenic differentiation after FN treatment were also examined. FN treatment activates myogenic
differentiation by increasing p38MAPK and decreasing JAK1-STAT1 phosphorylation levels, while
osteogenic induction was enhanced by p38MAPK dependent Smad, 1/5/8 signaling pathways in C2C12
progenitor cells.
Development of skeletal muscle cells is a strictly regulated process with diverse functions in organisms.
Myogenesis process can be divided into many different phases1. Mesoderm-derived structures generate the first
muscle fibers of the body. Proper and subsequent waves of additional fibers are generated along these template
fibers during embryonic myogenesis2. Skeletal muscle cells constitute 40% of the human body and play multiple
roles in locomotion and whole body metabolism. Muscle cells play a major role in energy production. Muscle
cells utilize higher than 70% of glucose and maintain lipid homeostasis. In addition, they maintain bone homeostasis via bone remodeling. They coordinate osteoblast-mediated bone formation with osteoclast-mediated bone
resorption3. In general, myogenic regulatory factors (MRFs) play an essential role in the fusion of muscle4,5.
Especially, basic helix-loop-helix (bHLH) transcription factor, myogenin, myogenic differentiation-1 (MyoD),
myogenic factors-5 (Myf5) and myogenic regulatory factor -4 are mainly involved in muscle development. In
addition, different intracellular signaling pathways such as p38 MAPK6,7, ERK/MAPK8, PI3K/AKT9,10, BMPs11
and JAKs-STATs12 regulate osteogenic and myogenic differentiation mediated by specific proteins via hormones,
cytokines and growth factor productions8,13–18.
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Figure 1. Effect of FN on cell viabilities measured with an Ez-cytox reagent. Cell viability was assayed with an
Ez-cytox reagent. At concentration below 50 µM, FN did not significantly affect the cell viabilities of C2C12 after
24 h of treatment. However, at concentrations greater than 50 µM, FN slightly affected their viability after 48 h of
treatment without significant (p < 0.05). The results are expressed as the mean ± SEM of six replicates.
Current treatment for osteoporosis is based on the use of anti-resorptive and bone-forming drugs. At the
same time, the continuous use of these drugs is highly associated with severe side effects. Therefore, effective
treatment approaches without side effects are urgently required for the enhancement of osteoblast and myogenic differentiation. Worldwide several researchers have attempted to identify lead compounds based on natural
products that activate osteoblasts19–23. Formononetin (FN) is a naturally occurring isoflavone occurring in many
natural sources including Astragalus membranaceus, Trifolium pretense, Glycyrrhiza glabra, Pueraria lobate and
Italian ryegrass. It considered a typical phytoestrogen which found predominantly in the red clover plant24. FN
shows diverse biological functions25. It acts as a neuroprotective26, and cardioprotective agent27. Furthermore,
FN has anticancer effects in lung28, colorectal29, and prostate cancers30,31. Also, FN reduces insulin resistance and
hyperglycemia32. FN influences the growth and immunological activities in broilers33. FN treatment promotes
early fracture healing and osteogenic potential through increasing vascular endothelial growth factor (VEGF),
VEGF receptor-2 and osteogenic specific markers in a rat fracture animal model34. Another report claimed that
the high-fat-diet-induced (HFD) obese mice treated with FN at different concentrations exhibited enhanced
osteoblast differentiation via restoring the mineralizing capacities and increasing myoblast specific markers such
as collagen type-1, RUNX2 and OCN in BMSCs cells than the BMSCs cells obtained from HFD alone treated
mice. Also, FN treatment decreased adipogenic potential in obese mice35. However, the molecular mechanisms
underlying the osteogenic and myogenic enhancement of FN in C2C12 mouse progenitor cells remain unclear.
Hence, this study aimed to identify the molecular action of FN in osteogenic and myogenic differentiation and its
impact on signal transduction pathways in mouse C2C12 progenitor cells.

Results

Effect of Formononetin (FN) on the viability of C2C12 progenitor cells.

Different concentrations
of FN on the viability of C2C12 progenitor cells at 24 and 48 h are presented in Fig. 1. At the concentration below
50 µM of FN did not affect cell viabilities at 24 h and 48 h, compared to control cells, whereas, at the concentration
greater than 50 µM, FN slightly affected cell viability after 48 h of treatment. However, there is no statistical significance (p < 0.05) between all concentrations of FN and control cells. At the same time, FN at the concentration of
less than 50 µM is the safer concentration for further experiments.

FN promotes both osteogenic and myogenic potential in C2C12 progenitor cells.

First, we analyzed whether FN treatment promoted osteogenic and myogenic activities in the presence of 2% horse serum
with 50 µg/mL Vitamin C and 10 mM β-glycerophosphate (HSCG). FN treatment potentially increased the levels
of early and delayed osteogenic markers such as ALP at 24, 48, 72 h, and calcium deposition at days 2, 4, and 6
(Fig. 2a–c). At the same time, microscopic views showed higher numbers of multinucleated myotubes than the
control cells (Fig. 3a). It prompted us to investigate the osteogenic and myogenic properties of FN simultaneously
in C2C12 cells cultured in the same medium.

FN treatment enhanced the expression of osteogenic and myogenic markers.

FN treatment
potently enhanced both osteogenic and myogenic differentiation. Therefore, we investigated the expression of
osteogenic specific transcripts, ALP, osteocalcin, RUNX2 and the expression of specific myogenic markers myoD,
myogenin, myosin heavy chain and its isoforms (MHC) at different time intervals. Quantitative-PCR analysis
revealed that HSCG significantly upregulated the osteoblast markers during differentiation, while FN combined
with HSCG potently enhanced the transcription of ALP, OCN, and RUNX2 (Fig. 2d). The ALP and RUNX2
expression levels were peaked at 24 h, whereas the OCN expression was upregulated throughout experimental
periods after FN treatment at a concentration of 2.5 µM (p < 0.05).Western blot results indicated that FN treatment strongly increased the expression of myogenic markers including myoD, myogenin, and myosin heavy
chain and its isoforms (MHC) at different time intervals during differentiation (Fig. 3b,c).

FN treatment Increased bone morphogenetic protein isoforms (BMPs). Next, we investigated the
osteogenic potential and enhancement of different forms of BMPs by FN in vitro. We found that FN treatment
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Figure 2. Increased ALP activity, calcium deposition and its markers gene by FN. Osteoblast differentiation was
induced with osteogenic induction medium (HSCG) in the presence of different concentrations (1–15 µM) of
FN and incubated for different days. (a) Cells were fixed in formalin and stained with Alizarin Red S for 30 min.
Cell images were obtained by EVOS cell image system at 10X. (b) Cell extracts were prepared and used for ALP
activity at 24, 48, and 72 h. (c) Alizarin Red S stain was extracted and quantified on day 2, 4 and 6 according
to the kit protocol. (d) The total RNA was extracted and reverse transcribed for quantification of mRNA by
qPCR. ALP, RUNX2 and osteocalcin mRNA levels were determined after normalization with β-actin. All values
represent mean ± SEM, n = 6 for ALP, calcium level and qPCR. Different letters a, b, c and d within a column
indicate significant differences between treatment and non-treatment (p < 0.05). Statistical significance was
performed using the general linear model with multivariate, post hoc test and comparisons with respective
controls.

potently upregulated the genes encoding BMP-2, BMP- 4, BMP- 6 BMP-7, and BMP-9 compared with the control
cells. The induction of BMP-2, BMP- 4 and BMP-7 was accelerated by FN until day 6, whereas the levels of BMP6 and BMP-9 were upregulated by day 2 and 4, respectively (Fig. 4a). Western blot results revealed that BMP-2
and BMP-4 protein expression was also induced after FN treatment compared with control on day 6 (Fig. 4b).
The results indicate that FN treatment induced osteogenic differentiation in C2C12 cells via induction of different
BMPs at different time points.

FN regulates different signaling pathways mediating osteogenic and myogenic differentiation. As FN showed both osteogenic and myogenic potential in the HSCG medium, we investigated the

mechanism of FN-mediated regulation of signal transduction pathways involved in osteogenic and myogenic differentiation of C2C12 progenitor cells. First, we analyzed the phosphorylation levels of JAK1, JAK2,
STAT1, STAT2 and Smad 1/5/8 in the differentiated cells on day 4 and 6 after FN treatment in the same medium
(Fig. 5a,b). FN treatment decreased JAK1/STAT1 and increased phosphorylated Smad 1/5/8 levels compared with
the control cells. However, JAK2/STAT2 phosphorylation was similar in control and FN-treated cells. We then
decided to investigate the precise mechanisms underlying osteogenic and myogenic differentiation. For myogenic
signaling confirmation, cells were treated with FN at a concentration of 2.5 µM in the myogenic differentiation
medium containing 2% horse serum (HS) for 6 days. Results suggested that FN treatment downregulated the
phosphorylated levels of JAK1/STAT1 compared with the control, while the Smad 1/5/8 phosphorylation was
not altered significantly between control and FN treatment in HS medium (Supplementary Fig. S1). It confirmed
that FN treatment increased osteogenic differentiation by increasing the levels of Smad 1/5/8 phosphorylation
while myogenic differentiation was promoted by decreasing the JAK1/STAT1 phosphorylation compared with
control cells.
Finally, we explored the role of p38MAPK, AKT, and ERK 1/2 pathways in FN-induced osteoblast and myoblast differentiation. The levels of p38MAPK, AKT, and ERKs phosphorylation were determined by western blot
with specific antibodies on day 4 and 6 following FN treatment in HSCG and HS medium (Figs 6a,b and S2). FN
treatment at 2.5 µM activated p38MAPK by increasing its phosphorylation level, while the levels of p44/42 and
AKT were not altered by FN when compared with the control cells. Therefore, a specific p38MAPK inhibitor
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Figure 3. FN treatment potently increased multinucleated myotube formation and its specific makers in the
HSCG medium. (a) Multinucleated myotubes were captured by EVOS cell image system at 10X and 20X. (b)
Protein lysates were prepared and used for immunoblotting using specific antibodies against key myogenic
markers myoD, myogenin, myosin heavy chains (MHC) and α-tubulin. (c) The intensity of protein reacted bands
was determined by densitometry using ImageJ software. Bars represent mean ± SEM for three replicates and
statistical analysis was performed using a general linear model with multivariate, post hoc test and comparisons
with respective controls. p < 0.05 level was considered significance between treatment and non-treatment.
was used in this study to establish FN-induced osteogenic and myogenic differentiation. Cells treated with p38
inhibitor alone at 10 μM in HSCG medium for 48 h decreased ALP activity, calcium deposition, and osteogenic
specific genes such as ALP, RUNX2 and osteocalcin mRNA expression compared with the control and FN-treated
cells. FN treatment combined with p38 inhibitor increased ALP activity, calcium deposition and osteogenic specific genes ALP, RUNX2 and osteocalcin mRNA expression compared with the control and cells treated with
p38 inhibitor alone (Fig. 7a–e.). In addition, cells treated with p38 inhibitor showed the reduced development of
multinucleated myotubes and myogenic specific markers myoD, and myogenin proteins whereas treatment of
p38 inhibitor together with FN at 2.5 μM reversed the p38 inhibitor-mediated inhibition of myotube formation
and its associated myogenic markers compared with control and p38 inhibitor-treated cells in HSCG (Fig. 8a–c).
Overall results suggest that FN treatment stimulated osteoblast differentiation by activating p38MAPK/Smad/
BMP signaling pathways, while myogenic differentiation was regulated by p38MAPK/JAK1/STAT1 signaling.
The key findings suggest that p38MAPK plays a significant role in both osteogenic and myogenic enhancement
of C2C12 progenitor cells by FN.

Discussion

FN is a phytoestrogen known to display a diverse spectrum of biological activities. Its functional role in osteogenic and myogenic differentiation is poorly demonstrated. Hence, we explored the role of FN in C2C12 cell
differentiation into osteogenic and myogenic lineage as well as the underlying signal transduction pathways. FN
showed a strong osteogenic and myogenic potential in C2C12 progenitor cells. Enhancement of alkaline phosphatase, OCN, RUNX and other factors such as BMPs, is important for the differentiation of C2C12 progenitor
cells into pre-osteoblasts. In mouse C2C12 cells, BMP- 2, 4, 6, 7, and 9 strongly induced the expression of early
osteogenic marker ALP and late osteogenic marker OCN36. OCN and osteopontin (OPN) are osteogenic markers
mediating the intermediate to late stages of osteogenesis. They enhance calcium deposition in the late phases of
osteogenesis37. The current study findings strongly reinforce the results discussed above. Indeed, FN treatment
increased ALP production and its mRNA expression in C2C12 cells in a time-dependent manner. ALP and its
mRNA expression were increased until 48hrs by FN treatment, whereas later, the levels of ALP and its mRNA
expression were downregulated. ALP has been widely accepted to be a strong and early marker of osteoblast
differentiation. It is responsible for the mineralization of the extracellular matrix (ECM)38. In addition, calcium
deposition and the gene encoding OCN at later stages of differentiation were accelerated by FN treatment as
compared with the control. Osteopontin and OCN are commonly used as early and late markers of osteogenic
differentiation respectively39.
FN treatment increased myogenic differentiation via upregulation of specific myogenic markers in a
time-dependent manner. Differentiation of myogenic cells is a highly organized process that is regulated by the
members of MyoD family including, MyoD and myogenin as well as the proteins in the myocyte enhancer factor
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Figure 4. Effects of FN on the expression of bone morphogenetic proteins (BMPs) in experimental cells. Cells
were differentiated with HSCG medium in the presence/absence of different concentration of FN (1.25–5 µM)
for 6 days. (a) BMPs mRNA expression in the experimental cells at different time points. (b) Levels of BMP-2
and BMP-4 protein expression in the experimental cells on day 6. Bars display mean ± SEM of six experimental
replicates. Different letters a, b, c, and d within a column indicates significant differences between groups
(p < 0.05). Statistical significance was performed using a general linear model with multivariate, post hoc test
and comparisons with respective controls.

(MEF2) family. The process of differentiation is highly complex and involves cell cycle termination, expression of
myogenic specific genes, and multinucleate myotube formation2,40,41. Myogenin plays an essential role in myoblast
differentiation. It acts at later stages of myogenesis to control their fusion42. The terminal differentiation of myoblasts into skeletal myocytes and fusion into myotubes is mediated by the controlled increase in the expression of
MyoD, Myf5, myogenin and MRF4, and the decreased the activity of cell cycle regulatory factors43. The activation
of myogenic regulatory factors (MRFs) including MyoD, myogenic factor 5 (Myf5), MRF4, and myogenin, also
regulates the expression of several muscle-specific genes, such as myosin heavy chain (MyHC) and creatinine
kinase in muscle fiber type maturation44–46.
Accordingly, FN treatment increased the formation of multinucleated myotubes in C2C12 cells compared
with the control, without affecting the cell viability or morphology. These results based on cell morphology and
analysis of specific myogenic markers suggests that FN increased the fusion of myoblasts into multinucleated
myotubes. Myogenin is a key factor required for muscle cell differentiation45. Its level is increased during the early
stages of differentiation, and decreased in fully differentiated cells. Also, MyHC and its isoforms are increased
during different stages of cellular differentiation47. The expression of myogenic specific proteins such as myoD,
myogenin, and muscle-specific genes myosin heavy chain and myosin heavy chain IIA during the differentiation
phase was analyzed. Our data suggested that FN treatment increased the expression levels of myoD, myogenin,
myosin heavy chain and myosin heavy chain IIA in differentiated cells compared with the control cells.
Bone morphogenetic protein induction and Smad1/5/8 signaling in osteogenic differentiation by FN were
examined, because BMPs are known to mediate bone formation via Smad signaling21,48,49. BMPs including, BMP2, BMP-4, BMP-6, BMP-7, and BMP-9 promote osteoblast differentiation of mesenchymal stem cells. BMP-250,
BMP-7, BMP-4, BMP-6, and BMP-9 exhibit strong osteogenic potential in C2C12 cells51. BMP-2 and BMP-7
induce rapid bone formation and increase the endogenous expression of BMP-452. BMP9 is recognized as one
of the most osteogenic BMPs. It promotes osteoblastic differentiation of mesenchymal stem cells (MSCs) both
in vitro and in vivo36,53–57. Bone morphogenetic protein -9 might provides a useful clinical strategy for the augmentation of bone regeneration and healing compared with other BMPs11. FN treatment significantly accelerated
the expression of BMP-2, BMP-4, BMP-6, BMP-7, and BMP-9. Furthermore, the levels of Smad 1/5/8 phosphorylation were increased compared with the control cells. Osteogenic activities of BMPs are known to activate
Smad-Runx258. Our results corroborate the findings of previous reports suggesting that FN treatment activates
the Smad1/Smad 5/Smad8 expression by increasing its levels of phosphorylation. In addition, FN treatment
increased the mRNA expression of Runx2 compared with the control suggesting that FN activated Smads/1/5/8
signaling during osteogenic differentiation by inducing BMP transcriptional activity.
Scientific Reports |
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Figure 5. FN role in JAKs-STATs and Smad1/5/8 signaling pathways in experimental cells. Cells were treated
with FN in HSCG media for six days. Proteins were harvested and the phosphorylation levels of JAKs-STATs
and Smad 1/5/8 proteins were analyzed on day 4 and 6 by immunoblotting using specific antibodies against
targets. (a) JAKs-STATs and Smad 1/5/8 phosphorylation level after treatment with FN in HSCG medium. (b)
The intensity of protein bands was quantified by densitometry using ImageJ software. Bars display mean ± SEM
of three experimental replicates. *p < 0.05 represents a statistically significant difference between control and
treatment.

Figure 6. Effect of FN on p38MAPK, AKT and p44/42 signaling pathways in experimental cells. Cells were
treated with 2.5 μM FN in the presence of HSCG media for six days. Proteins were then extracted and analyzed
by immunoblotting using specific antibodies against p38MAPK, AKT, and p44/42. (a) Regulation of p38MAPK,
AKT, and p44/42 signaling by FN treatment. (b) The intensity of protein bands was determined by ImageJ
software. Bars display mean ± SEM of three experimental replicates. *p < 0.05 indicates a statistically significant
difference between treatment and non-treatment.

As FN showed both osteogenic and myogenic potential, we investigated its role in the regulation of signaling
pathways involved in osteogenic and myogenic differentiation of C2C12 cells. First, we analyzed the phosphorylation levels of JAK1, JAK2, STAT1, and STAT2 in differentiated cells on day 4 and 6 post-treatment with FN.
It is known that the JAKs/STATs pathway plays an essential role in myogenic differentiation. The JAK1/STAT1/
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Figure 7. A competitive study between FN (2.5 μM) and p38 inhibitor (10 μM) upon osteogenic enhancement
of C2C12 cells. Cells treated with FN in the presence/absence of SB203580 (10 µM) for 48 h. (a) Experimental
cells were fixed and stained with Alizarin Red S for 30 min. Cell images were obtained using the EVOS cell
image system at 10X, arrows indicate calcium deposition in cells. (b) Proteins were extracted and separated by
SDS-PAGE for immunoblotting with antibodies against pp38, pSmad1/5/8 and α-tubulin. (c) Cell extracts were
prepared and used for the determination of ALP activity at 48 h. (d) Cells stained with Alizarin Red S stain were
extracted and quantified on day 6 according to the kit protocol. (e) RNA was extracted from the experimental
cells and subjected to cDNA synthesis for quantification of ALP, RUNX2 and osteocalcin mRNA expression.
All values represent mean ± SEM, n = 6 for ALP, calcium level and qPCR. Different letters a, b, c and d within a
column indicate significant differences between treatment and non-treatment groups (p < 0.05).

STAT3 axis is involved in myoblast proliferation, which prevents premature differentiation into myotubes59.
JAK2/STAT2/STAT3 expression appears to positively regulate differentiation, indicating that STAT3 elicits specific responses at various times during myogenesis. Inhibition of JAK2 expression abrogates myogenic differentiation. At the same time, JAK1 knockdown accelerates myogenic differentiation, while proliferation is inhibited in
C2C12 cells and primary myoblasts60. In addition, STAT1 knockdown promotes myogenic differentiation in both
primary and immortalized myoblasts59. Therefore, we analyzed whether FN altered JAK/STAT signaling pathways
involved in the differentiation. Our data showed that FN treatment downregulated JAK1/STAT1 expression by
decreasing their phosphorylation level. However, the phosphorylation level of JAK2/STAT2 was not altered significantly between control and FN-treated cells. These results confirm that FN regulated myogenic differentiation
via inhibition of JAK1/STAT1 by decreasing their phosphorylation.
At last, we determined the role of FN on p38MAPK, AKT and ERK1/2 signaling pathways involved in osteogenic and myogenic differentiation of C2C12 cells. Extracellular signals regulating both osteogenic and myogenic
signals are transduced to the nucleus by mitogen- activated-kinases. Inhibition of p38 prevents the differentiation
mechanism in myogenic cell lines and human primary myocytes. Inhibition of p38 also prevents induction of
early markers such as myogenin, p21, and late (MHC) myogenic markers8. In addition, p38 MAPK phosphorylation plays a key role in the regulation of ALP production during MC3T3-E1 cells differentiation. Inhibition
of p38 MAPK by specific inhibitors decreased the ALP expression and mineral deposition in MC3T3-E1 cells61.
Another study reported that p38 MAPK was required for the expression of ALP and osteocalcin while ERKs
were necessary for OC expression only62. Several investigators have reported that the ERK groups of MAPKs
also play a role in myogenic differentiation. While some investigators have indicated that ERK members inhibit
differentiation63,64 others reported that ERKs are positive regulators of myogenesis65. Akt signaling also plays
a major function in hypertrophy and contributes to the myotubes size increases in C2C12 cells21. In addition,
IGF-phosphoinositide 3-kinase (PI3K)-Akt signaling has been shown to induce myogenic differentiation by stimulating genes specific for myogenic markers such as myogenin, MyoD and MEF266,67. The current study demonstrates that treatment of FN significantly increased the p38 MAPK expression at 2.5 μM of FN without altering
Akt or ERKs phosphorylation levels. These results suggest that FN enhanced both osteogenic and myogenic
induction via p38 signaling without altering Akt or ERKs pathways. Furthermore, the augmentation of the p38
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Figure 8. A competitive study between FN (2.5 μM) and p38 inhibitor (10 μM) upon myogenic enhancement
in C2C12 cells. Cells treated with FN in the presence/absence of SB203580 (10 µM) for 48 h. Proteins were
resolved by SDS-PAGE and incubated with specific antibodies targeted against pp38, myoD, myogenin, and
α-tubulin for immunoblotting analysis. (a) Key myogenic proteins expression in the experimental cells. (b)
Quantitative analysis of protein bands was performed using the ImageJ program. (c) Myotubes formation in the
experimental cells. Bars represent mean ± SEM of three experimental replicates. Different letters a, b, c and d
within a column indicate significant differences between treatment and non-treatment groups (p < 0.05).

pathway by FN treatment in differentiated cells was investigated using specific inhibitors. Cells were treated with
SB-203580; a p38 inhibitor potently reduced both osteogenic and myogenic differentiation by downregulating
specific myogenic markers such as myogenin, myoD, and osteogenic markers including the level of ALP, calcium
accumulation and the specific gene expression ALP, RUNX2 and OCN in cells. By contrast, FN treatment with
p38 inhibitor accelerated both osteogenic and myogenic specific genes and protein expression.

Conclusion

In conclusion, the current data suggest that FN treatment significantly increases ALP activity, calcium deposition,
and the expression of osteogenic key markers including ALP, RUNX2, OCN and myogenic specific genes such as
myogenin, MyoD, myosin heavy chains. BMP- 2, BMP-4, BMP-6, BMP-7, and BMP-9 levels were enhanced by the
FN treatment in a concentration and time-dependent manner. FN treatment activates myogenic differentiation by
increasing p38MAPK and decreasing JAK1-STAT1 phosphorylation levels, while osteogenic differentiation was
enhanced by p38MAPK dependent Smad, 1/5/8 signaling pathways in C2C12 progenitor cells. FN might represent a potential lead compound to promote osteogenic and myoblast differentiation in C2C12 progenitor cells,
especially regulating the progression of osteogenic enhancement and myotube morphology.

Methods

Cell culture and reagents. The C2C12 mouse myogenic progenitor cells line was procured from the
American Type Culture Collection [ATCC, Rockwille, MD, USA]. Dulbecco’s modified Eagle’s medium [DMEM30-2002] and fetal bovine serum (FBS-30-2020) were procured from ATCC [Rockwille, MD, USA]. Kits for
mRNA extraction, iScript cDNA synthesis and qPCR were purchased from Bio-Rad [Biorad- California, USA].
FN, Vitamin C and β-glycerophosphate were obtained from Sigma Aldrich (St. Louis, MO, USA). SB203580
inhibitor was provided by Cell Signaling Technology (Danvers, MA, USA). BMP-4 BMP-2, MyoD, Myogenin,
α-tubulin, myosin heavy chain (MHC), MHCIIa, MHCIIc, JAK/pJAK1(Tyr1034/1035), JAK2/pJAK2(Tyr1008),
STAT1/pSTAT1(Ser727), STAT2/pSTAT2(Tyr690), Smad/Smad1(ser463/465)/5(ser 463/465)/9(Ser465/467),
p38MAPK/pp38MAPK (Thr180/Tyr182), ERKs/ERK(Thr202/Tyr204) and Akt/pAkt (Ser473) were acquired
from Cell Signaling Technology (Danvers, MA, USA), Abcam (Cambridge,UK) and Santa Cruz Biotechnology
(Dallas,Texas, USA).
Formononetin preparation. FN stock solution was prepared in DMSO. The fresh working FN was prepared in DMEM-30-2002 from the stock FN for every treatment.
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Determination of cell viability. Ez-cytox assay kit (iTSBiO, Seoul, Korea) was used to determine the
effects of FN on cell viability. In details, the cells (C2C12-ATCC, USA) at the density of 1 × 104 were treated with
different concentrations of FN after 24 h seeding in 96 well plates and incubated at 37 °C with 5% CO2 for 24 h
and 48 h. After incubation, ten microliters of WST reagent was added to each well and incubated at 37 °C with 5%
CO2 for 1 to 2 h. The cell viability was measured at 450 nm using a Packard SpectraCount Absorbance Microplate
Reader [Packard Instrument Co., Downers Grove, IL].
Osteogenic differentiation. C2C12 progenitor cells were seeded into 6-well (or) 12-well cell culture plates

at a density of 5 × 104 or 2.5 × 104 cells/well, respectively. Cells were cultured in 10% FBS in DMEM (ATCC302002) medium and incubated at 37 °C with 5% CO2. Osteogenic induction was performed according to the previous method68 with modifications. The growth medium was replaced by osteogenic differentiation medium
containing vitamin C (50 µg/mL) and β-glycerophosphate (10 mM) in the presence of 2% horse serum (HSCG)
medium after cells reached 80–90% confluence. FN at different concentrations was exposed to the cells in the
HSCG medium for every 48 h during the experimental periods.

Myogenic differentiation. C2C12 cells were seeded into 6-well (or) 12-well cell culture plates at a density of

5 × 104 or 2.5 × 104 cells/well, respectively. The cells were cultured in 10% FBS in DMEM DMEM (ATCC30-2002)
medium and incubated at 37 °C with 5% CO2. Myogenic differentiation was induced with myogenic differentiation medium consisting of DMEM with 2% horse serum (HS) after cells reached 80–90% confluence. The growth
medium was replaced by 2% HS medium for every 48 h with different concentration of FN until the end of the
experimental periods69.

ALP quantification.

Experimental cells were harvested at different time points and washed with cold PBS
three times. Cells were suspended in 500 µL of assay buffer and homogenized using a homogenizer. Cell lysates
were centrifuged at 12000 g, 4 °C for 15 min. The supernatants were collected and stored on ice for further assay.
The alkaline phosphatase activity of samples was measured using the ALP assay kit (Abcam, Cambridge, MA,
USA).

Calcium staining and quantification.

The culture medium was aspirated and washed with PBS twice.
Cells were fixed with 1 mL of 4% paraformaldehyde in PBS for 15 min at room temperature. Subsequently, after
carefully removing the fixative, the cells were washed three times with dH2O. After draining the water completely,
1 mL of 2% Alizarine Red S stain solution was slowly added to each well. Plates were then incubated at the room
for 30 min temperature. After removing excess dye, plates were washed 3–5 times with dH2O followed by the
addition of water 1 mL to each well. Images were obtained using an inverted microscope (CKX41, Olympus
Corporation, Tokyo Japan]. Calcium deposition in differentiated cells was quantified using the Alizarin Red S
staining quantification kit according to the manufacturer’s protocol (Science Cell, Carlsbad, CA).

Real-time quantitative reverse transcription PCR. Total RNA of the experimental cells were extracted
and quantified using RNeasy lipid mini Kit (Qiagen, MD, USA) and Spectramaxi3(Molecular Devices, California,
USA), respectively. Five hundred nanograms of total RNA used to cDNA synthesis using an iScript cDNA synthesis kit (Biorad, California, USA). Gene expression patterns were quantified by SYBR Green-based qPCR using
gene-specific primers: ALP(R-gctccacaaacgagaaaagc; F-tccttcacgccacacaagta), BMP-2(R-acgtcctcagcgagtttgag;
F-ctctccagccggtggtct), BMP-4 (R-cagcatcccagaaaatgagg; F-ttatacggtggaagccctgt), BMP-6 (R-gcagcagcagcagcagac;
F-ctcttcgtcgtcattggaca),BMP-7(R-gggcttctcctacccctaca; F-tccactaggttgacgaagctc), BMP-9(R-ggagaggagggtgtctttga;
F-gttttgtcctgggagggaat), OC(R-agtccccagcccagatcc; F-ccgtagatgcgtttgtaggc); RUNX2 (R-caacagagggcacaagttct;
F-gctcggatcccaaaagaag) β-actin (R-tatggaatcctgtggcatcc; F-tggtaccaccagacagcact) on a CFX 96 Real-Time PCR
detection system (Biorad, California, USA). Expressions of target genes were quantified after normalization with
β-actin70.
Protein extraction and immunoblotting.

Proteins lysates were prepared from the cells using
Radioimmunoprecipitation assay buffer (RIPA) (Rockland, Limerick, PA) with 1X protease and phosphatase
inhibitors (Roche, Basel, Switzerland and Sigma Aldrich, St. Louis, USA). Cells were washed three times with
PBS. After the addition of the required volume of RIPA lysis buffer based on the plate types, cells were incubated
at 4 °C for 5 min. Cells were scraped rapidly with a cell scraper (TPP, Trasadingen, Switzerland) to remove and
lyse residual cells. The cell lysate was transferred to a 2 mL tube and centrifuged at 8000 g for 10 min at 4 °C.
Protein concentration was quantified by the Pierce BCA protein assay kit (Thermofisher Scientific, Massachusetts,
USA). Protein samples were separated by pre-casting-SDS-PAGE (4–12%, Biorad- California, USA) and blotted onto polyvinylidene difluoride (PVDF) membranes (Trans-blot Turbo transfer system, Biorad, California,
USA). Immunoblotting was performed according to the western breeze chemiluminescence kit (Invitrogen,
Massachusetts, USA) using rabbit monoclonal and polyclonal antibodies. All primary antibody reactions were
carried out at 4 °C for overnight (Cell Signaling Technology antibodies 1:1000; Santa Cruz Biotechnology antibodies 1.500; Abcam antibodies 1:1000) against specific proteins69. The HRP-conjugated secondary antibody was
used for the detection of primary antibodies (Cell Signaling Technology, Danvers, MA, USA). Band signals were
analysed with an enhanced chemiluminescence kit (Bio-Rad- California, USA) on a chemiluminescence imaging
system (Davinch gel imaging system, Seoul, South Korea). The intensity of immunoreactive bands was quantified
with ImageJ software - 1.49 version(32 bit), (Wayne Rasband, National Institute of Health, USA).
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Statistical analysis. The data generated from experiments were subjected to one-way ANOVA and multivariate comparisons analysis using Statistical Package for the Social Sciences (SPSS-16). Less than 0.05 was
considered as Statistical significance between the treatment and non-treatment.

Data Availability

The data generated and analyzed for the current study are available from the corresponding author upon reasonable request.
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